Skip to content
Cubicin(daptomycin)
Cubicin, Dapzura Rt (daptomycin) is a protein pharmaceutical. Daptomycin was first approved as Cubicin on 2003-09-12. It is used to treat bacteremia, bacterial infections, and bacterial skin diseases in the USA. It has been approved in Europe to treat bacteremia, bacterial endocarditis, bacterial skin diseases, gram-positive bacterial infections, and soft tissue infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
cardiovascular diseasesD002318
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Dapzura rt (generic drugs available since 2016-03-25, discontinued: Cubicin, Cubicin rf)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Daptomycin
Tradename
Company
Number
Date
Products
DAPTOMYCIN IN 0.9% SODIUM CHLORIDEBaxterN-213645 RX2023-02-27
4 products, RLD, RS
DAPZURA RTBaxterN-213645 PEND2022-01-25
1 products, RLD
DAPTOMYCINHospiraN-210282 RX2021-06-21
2 products, RLD, RS
DAPTOMYCINSagent PharmaceuticalsN-208385 RX2017-09-12
1 products, RLD, RS
DAPTOMYCINXelliaN-209949 RX2017-10-20
1 products, RLD, RS
DAPTOMYCINXelliaN-217415 RX2023-01-30
2 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cubicinNew Drug Application2022-11-22
daptomycinANDA2023-06-06
dapzura rtNew Drug Application2022-01-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacteremiaEFO_0003033D016470R78.81
bacterial infections—D001424A49
bacterial skin diseases—D017192—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Daptomycin, Daptomycin In 0.9% Sodium Chloride, Baxter Hlthcare Corp
111731892041-03-11DPU-3294
Daptomycin, Daptomycin, Hospira
96559462033-09-11DPU-3175
103575352033-09-11DPU-3176
Daptomycin, Cubicin, Cubist Pharms Llc
91384562030-11-23DP
80036732028-09-04U-1180
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01X: Other antibacterials in atc
— J01XX: Other antibacterials in atc
— J01XX09: Daptomycin
HCPCS
Code
Description
J0878
Injection, daptomycin, 1 mg
Clinical
Clinical Trials
87 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
BacteremiaD016470EFO_0003033R78.81—447—15
EndocarditisD004696EFO_0000465I33—1—315
Staphylococcal infectionsD013203A49.01—122—5
Soft tissue infectionsD018461—21115
SepsisD018805A41.911—114
Infectious skin diseasesD012874—111—3
Renal insufficiencyD051437HP_0000083N191—11—3
CellulitisD002481EFO_0003035L03.90———3—3
Bacterial endocarditisD004697EFO_1000830—111—3
OsteomyelitisD010019EFO_0003102M86—1—1—2
Show 12 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—12—36
Gram-positive bacterial infectionsD016908211——4
Bacterial pneumoniaD018410EFO_1001272J15.9——2——2
Surgical wound infectionD013530——1—12
Staphylococcus aureusD013211NCBITaxon_1280—11——2
Critical careD003422——1——1
Gram-positive bacteriaD006094——1——1
Cross infectionD003428——1——1
Liver cirrhosisD008103EFO_0001422K74.0—11——1
AscitesD001201HP_0001541R18—11——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial infectionsD001424A49—1——12
NeutropeniaD009503D70—1——12
NeoplasmsD009369C80—1——12
Pneumococcal meningitisD008586EFO_1001114G00.1—1———1
FeverD005334HP_0001945R50.9—1———1
Hot flashesD019584—1———1
SweatingD013546—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MeningitisD008581EFO_0000584G031———12
Chronic kidney failureD007676EFO_0003884N18.62————2
Subcutaneous injectionsD0072791————1
PharmacokineticsD0105991————1
Drug interactionsD0043471————1
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-related side effects and adverse reactionsD064420T88.7————22
Fatal outcomeD017809————11
Cerebral hemorrhageD002543————11
Subarachnoid hemorrhageD013345EFO_0000713I60————11
Drug monitoringD016903————11
MediastinitisD008480J98.51————11
Heart-assist devicesD006353————11
Septic shockD012772A48.3————11
Chronic renal insufficiencyD051436N18————11
Acute kidney injuryD058186HP_0001919N17————11
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDAPTOMYCIN
INNdaptomycin
Description
Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.
Classification
Small molecule
Drug classaptamers, classical and mirror; antibiotics (Streptomyces strain)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C
Identifiers
PDB—
CAS-ID103060-53-3
RxCUI22299
ChEMBL IDCHEMBL387675
ChEBI ID600103
PubChem CID21585658
DrugBankDB00080
UNII IDNWQ5N31VKK (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Cubicin - Merck Sharp & Dohme
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 12,650 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15,015 adverse events reported
View more details